Dr. K K Aggarwal, President Heart Care Foundation of India and Group Editor in Chief MEDtalks, will talk on the topic whether DCGI (Drug Controller General of India) should withdraw febuxostat from the market in this video. Febuxostat is given to reduce uric acid in the body. It is often misused drug in our country. If the uric acid levels are more than 10 and patient is asymptomatic then no need to treat them. High uric acid is the indicator of metabolic syndrome. It is been rejected twice by USFDA stating that it causes cardiovascular complications.